In 2010, important research into the systemic autoinflammatory diseases has confirmed and extended the role of IL-1 inhibition in hereditary autoinflammatory disorders, demonstrated a novel treatment for a dangerous complication, and expanded the spectrum of systemic autoinflammatory diseases while further implicating autoinflammation in the complications of the metabolic syndrome.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Applications of reconstituted inflammasomes in a cell-free system to drug discovery and elucidation of the pathogenesis of autoinflammatory diseases
Inflammation and Regeneration Open Access 03 May 2017
-
Macrophagic CD146 promotes foam cell formation and retention during atherosclerosis
Cell Research Open Access 13 January 2017
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Kastner, D. L., Aksentijevich, I. & Goldbach-Mansky, R. Autoinflammatory disease reloaded: a clinical perspective. Cell 140, 784–790 (2010).
Masters, S. L., Simon, A., Aksentijevich, I. & Kastner, D. L. Horror autoinflammaticus: the molecular pathology of autoinflammatory disease. Annu. Rev. Immunol. 27, 621–668 (2009).
Neven, B. et al. Long-term efficacy of the interleukin-1 receptor antagonist anakinra in ten patients with neonatal-onset multisystem inflammatory disease/chronic infantile neurologic, cutaneous, articular syndrome. Arthritis Rheum. 62, 258–267 (2010).
Lepore, L. et al. Follow-up and quality of life of patients with cryopyrin-asociated periodic syndromes treated with anakinra. J. Pediatr. 157, 310–315 (2010).
Bodin, K. et al. Antibodies to human serum amyloid P component eliminate visceral amyloid deposits. Nature 468, 90–97 (2010).
Duewell, P. et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature 464, 1357–1361 (2010).
Goldbach-Mansky, R. Blocking interleukin-1 in rheumatic diseases. Ann NY Acad. Sci. 1182, 111–123 (2009).
Kubota, T. & Koike, R. Cryopyrin-associated periodic syndromes: background and therapeutics. Mod. Rheumatol. 20, 213–221 (2010).
Lachmann, H. J. et al. Natural history and outcome in systemic AA amyloidosis. N. Engl. J. Med. 356, 2361–2371 (2007).
Pepys, M. B. et al. Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis. Nature 417, 254–259 (2002).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Ombrello, M., Kastner, D. Expanding clinical spectrum and broadening therapeutic horizons. Nat Rev Rheumatol 7, 82–84 (2011). https://doi.org/10.1038/nrrheum.2010.229
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrrheum.2010.229
This article is cited by
-
Is there a relationship between serum omentin level and acute phase response in patients with familial Mediterranean fever?
Clinical Rheumatology (2021)
-
Applications of reconstituted inflammasomes in a cell-free system to drug discovery and elucidation of the pathogenesis of autoinflammatory diseases
Inflammation and Regeneration (2017)
-
Macrophagic CD146 promotes foam cell formation and retention during atherosclerosis
Cell Research (2017)
